Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient

Gastroenterology

Volumn 120, Issue 3, 2001, Pages 594-606

  Laine, Loren ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CELECOXIB; CORTICOSTEROID; DICLOFENAC; IBUPROFEN; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

AGE; CLINICAL FEATURE; DIGESTIVE SYSTEM PERFORATION; DRUG SAFETY; GASTRODUODENAL ULCER; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STOMACH EROSION; STOMACH OBSTRUCTION;

EID: 0035112660     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2001.21907     Document Type: Article

References (90)

1. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly
2. Effect of aspirin on the human stomach in normals: Endoscopic comparison of damage produced one hour, 24 hours, and 2 weeks after administration
3. Gastric adaptation occurs with aspirin administration in man
4. 2: An endoscopic study
5. Effects of 24 hours of aspirin, Bufferin, paracetamol and placebo on normal human gastroduodenal mucosa
6. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other non-steroidal anti-inflammatory drugs
7. A randomized trial comparing the effect of rofecoxib, a COX-2-specific inhibitor, to ibuprofen on the gastroduodenal mucosa of osteoarthritis patients
8. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. A randomized, double-blind, placebo-controlled trial
9. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial
10. Nonsteroidal anti-inflammatory drug gastropathy
11. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: Cohort study
12. Non-steroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates
13. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons
14. NSAID induced gastrointestinal complications: The ARAMIS perspective-1997
15. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons
16. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, doubleblind, placebo-controlled trial
17. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial
18. Comparison of upper intestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
19. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations
20. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin - Analysis of gastrointestinal bleeding during the UK-TIA trial
21. Risk stratification of upper gastrointestinal bleeding in cardiovascular patients on low-dose aspirin. A cohort study
22. Prophylactic aspirin and risk of peptic ulcer bleeding
23. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans
24. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product
25. Risk for serious gastrointestinal complications related to the use of nonsteroidal anti-inflammatory drugs. A meta-analysis
26. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs
27. Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years. A large health maintenance organization cohort study
28. Non-steroidal anti-inflammatory drugs and complications: A risk factor analysis for clinical decision-making
29. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease
30. Corticosteroid use and peptic ulcer disease: Role of nonsteroidal anti-inflammatory drugs
31. The association of nonsteroidal anti-inflammatory drugs with gastrointestinal tract bleeding
32. Non-steroidal anti-inflammatory drug use and increased risk for peptic ulcer in elderly persons
33. Risk factors for serious nonsteroidal-induced gastrointestinal complications: Regression analysis of the MUCOSA trial
34. Peptic ulcer bleeding: Accessory risk factors and interactions with non-steroidal anti-inflammatory drugs
35. Risk assessment after acute upper gastrointestinal haemorrhage
36. Dyspepsia in NSAID users: The size of the problem
37. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use
38. Omeprazole vs misoprostol: Different effectiveness in healing gastric and duodenal ulcers vs erosions in NSAID users - The OMNIUM study
39. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration
40. Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: A case control study
41. Gastrointestinal bleeding: Dyspeptic symptoms and clinical course in relation to use of non-steroidal antiinflammatory drugs
42. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study
43. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers
44. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study
45. Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study
46. Prospective randomized trial of H. pylori eradication versus maintenance omeprazole to prevent recurrent upper gastrointestinal hemorrhage in high-risk aspirin and non-aspirin NSAID users
47. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: A case control study
48. Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly. A case-control study
49. Peptic ulcer bleeding in the elderly: Relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs
50. Interaction between Helicobacter pylori and non-steroidal anti-inflammatory drugs in peptic ulcer bleeding
51. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID use
52. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low dose aspirin
53. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis
54. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs
55. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs
56. Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal prostaglandins
57. Salicyl-salicylic acid causes less gastroduodenal damage than enteric-coated aspirin: An endoscopic comparison
58. A randomized double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production
59. Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis
60. Comparison of the upper gastrointestinal safety of Arthrotec® 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers
61. Gastrointestinal safety profile of nabumetone: A meta-analysis
62. Comparative GI toxicity of NSAIDs
63. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients
64. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: Results of the safety and efficacy large-scale evaluation of cox-inhibiting therapies (SELECT) trial in osteoarthritis
65. Gastrointestinal safety profile of meloxicam: A meta-analysis and systematic review of randomized controlled trials
66. Effect of ranitidine gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs
67. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: Controlled trial of ranitidine
68. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs
69. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs
70. Duodenal and gastric ulcer prevention with misoprostol in arthritic patients taking NSAIDs
71. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: A comparison of three regimens
72. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs
73. Evidence that lansoprazole is effective in preventing NSAID induced ulcers
74. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study
75. Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study
76. TM, MK-0966, 4-(4″methylsulfonyl)-3-phenyl-2-(5H)-furanone): A potent, selective and orally active cyclooxygenase-2 inhibitor - Pharmacological and biochemical profiles
77. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor Of COX-2
78. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
79. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison
80. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: Retrospective cohort study of an elderly population
81. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis
82. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs
83. Resource utilization and cost of care for rheumatoid arthritis in a managed care setting. The importance of drug and surgery costs
84. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs
85. Treatment with rofecoxib required less gastrointestinal (GI) co-medication and fewer GI procedures than nonspecific cyclooxygenase inhibitors (NSAIDs)
86. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
87. Gastrointestinal (GI) co-therapy, procedures, and hospitalizations in a GI outcomes study of rofecoxib vs. naproxen in rheumatoid arthritis